Clinical trials: Allergic Conjunctivitis
- Condition Allergic Conjunctivitis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Allergic Conjunctivitis
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers
- Trial name
- NCT00569777
- Testing
- K-Lens (generic name not established) and Ketotifen
- Where
- 3 sites in United States
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Allergic Conjunctivitis
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01479374
- Testing
- AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2%
- Volunteers
- 397 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
Safety study for bepotastine besilate ophthalmic solution in normal volunteers
- Trial name
- NCT00586625
- Testing
- Bepreve
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
AGN-229666 for the Treatment of Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
- Trial name
- NCT01754766
- Testing
- AGN-229666, vehicle of AGN-229666
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Allergan
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Chronic Allergic Conjunctivitis
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02988882
- Testing
- Dexamethasone
- Volunteers
- 86 people
- Sponsor
- Ocular Therapeutix, Inc.
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00769886
- Testing
- Ketotifen/naphazoline, Ketotifen, Naphazoline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT02978183
- Testing
- ST266, Saline (0.9% NaCl)
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Allergic Conjunctivitis
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.
- Trial name
- NCT01159015
- Testing
- KetoNaph, Vehicle
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
- Trial name
- NCT01346371
- Testing
- Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minnesota Eye Consultants, P.A.
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Chronic Allergic Conjunctivitis
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02062905
- Testing
- Dexamethasone
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Allergic Conjunctivitis
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01551056
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Aciex Therapeutics, Inc.
Allergic Conjunctivitis
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT00882687
- Testing
- Lifitegrast
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shire
Allergic Conjunctivitis
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic…
- Trial name
- NCT01107405
- Testing
- Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- AC-170 (NCT01332188)
- Testing
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Conjunctivitis
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
- Trial name
- NCT04709575
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 353 people
- Sponsor
- Regeneron Pharmaceuticals
Conjunctivitis, Vernal
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
The primary objective of this study is: To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.
- Trial name
- NCT00328653
- Testing
- Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Santen SAS